GLP-1 Drug-Delivery Device Ecosystem: Combination Products, Auto-Injectors, and Regulatory Pathways (2026)

The GLP-1 Revolution and Its Device Implications

The GLP-1 receptor agonist market has become the defining pharmaceutical story of the decade. What began as a class of injectable diabetes medications has transformed into a multi-hundred-billion-dollar therapeutic category spanning diabetes, obesity, cardiovascular risk reduction, and emerging indications from kidney disease to neurological disorders. As of mid-2026, the market includes Wegovy (injectable semaglutide), Ozempic (injectable semaglutide for diabetes), Zepbound (injectable tirzepatide), Mounjaro (injectable tirzepatide for diabetes), Wegovy oral (25 mg tablet, approved December 2025), and the newly approved Foundayo (oral orforglipron, approved April 2026) -- the first oral small-molecule GLP-1 receptor agonist.

Behind every injectable GLP-1 product is a drug-delivery device: a pre-filled pen injector, an auto-injector, or a cartridge-based injection system. These devices are not passive containers. They are regulated medical devices that must meet rigorous safety, performance, and usability standards. They are combination products, and they sit at the intersection of pharmaceutical and device regulation in ways that create unique challenges for manufacturers, regulators, and patients.

The device side of the GLP-1 ecosystem is undergoing its own revolution. Connected injection systems are entering the market. Dual-chamber cartridge devices that automate reconstitution of lyophilized drug products are reaching commercial readiness. Oral delivery platforms are challenging the dominance of injection devices. And the sheer scale of GLP-1 demand -- with 30 or more compounds in active development for obesity alone -- is straining the global supply chain for injection device components, from pen mechanisms to glass cartridges to sterile needles.

This guide provides a comprehensive analysis of the GLP-1 drug-delivery device ecosystem as it stands in 2026: the market landscape, the device platforms, the regulatory pathways for combination products in both the US and EU, the enforcement actions reshaping the compounding market, the supply chain dynamics, and the outlook for 2027 and beyond. It is written for medical device regulatory professionals, combination product developers, and anyone working at the intersection of drug delivery and device regulation.

GLP-1 Market Landscape in 2026

FDA-Approved GLP-1 Products and Their Delivery Formats

The GLP-1 receptor agonist market in 2026 is defined by an expanding portfolio of approved products, each with distinct delivery mechanisms:

The approval of Foundayo in April 2026 marked a significant milestone: the first oral small-molecule GLP-1 receptor agonist. Unlike oral semaglutide (Wegovy oral), which requires specific food and water restrictions due to its peptide-based formulation and reliance on an absorption enhancer (SNAC), orforglipron is a non-peptide small molecule that can be taken without these restrictions. This distinction has important implications for the device ecosystem, as it may shift a portion of patient demand away from injection devices for obesity indications.

Medicare GLP-1 Bridge Access Program

Access and affordability remain central to the GLP-1 market dynamics. Starting July 1, 2026, CMS will provide access to Foundayo, Wegovy, and the Zepbound KwikPen for eligible Medicare Part D beneficiaries through a bridge program running through December 31, 2027. This program is expected to significantly expand the patient population using these therapies, with downstream effects on device demand, supply chain planning, and post-market surveillance data volumes.

Pipeline Products and Their Device Implications

The GLP-1 pipeline remains exceptionally active, with several products at late-stage development that will require new or modified delivery devices:

CagriSema is particularly notable from a device perspective. As a combination of two peptides (semaglutide and cagrilintide), it may require a dual-chamber drug-delivery system that keeps the two components separate until the point of injection, or a co-formulation that demands specialized pen injector technology. SHL Medical's Reunite dual-chamber cartridge autoinjector and Ypsomed's LyoTwist dual-chamber monodose device (launched February 2026) are both positioned to address this need.

Drug-Delivery Device Platforms for GLP-1 Therapies

Pre-Filled Pen Injectors

Pre-filled pen injectors remain the dominant delivery platform for GLP-1 injectables. These devices combine a drug reservoir (typically a glass cartridge), a dosing mechanism, a needle, and a user interface in a single disposable unit. The pens used for Wegovy, Ozempic, Zepbound, and Mounjaro each represent years of human factors engineering, manufacturing optimization, and regulatory negotiation.

Key design considerations for GLP-1 pen injectors include:

• Dose accuracy: Pen injectors must deliver the prescribed dose within tight tolerance limits, typically plus or minus 5 percent or tighter, across the full range of labeled doses and environmental conditions.
• Needle gauge and length: GLP-1 injections are subcutaneous. Needle design must balance injection force (which affects dose accuracy and patient comfort) with patient perception of pain and ease of use.
• Dose selection interface: Many GLP-1 therapies involve dose escalation (starting at a low dose and titrating upward). The pen interface must make dose selection intuitive and provide clear confirmation of the selected dose.
• Injection force profile: The force required to expel a viscous GLP-1 formulation through a fine needle must remain within limits that patients with limited hand strength (a common issue in the diabetic and obese patient population) can manage.
• Temperature sensitivity: Most injectable GLP-1 products require refrigeration before first use and have specific room-temperature storage windows after first use. The pen device must protect the drug product within these constraints.

Dual-Chamber Reconstitution Devices

Lyophilized (freeze-dried) formulations are increasingly important for next-generation GLP-1 products, particularly combination therapies like CagriSema and higher-dose formulations that cannot be maintained in stable liquid form. Lyophilized products require reconstitution -- mixing with a diluent immediately before injection -- which adds complexity and user error risk.

Two device platforms have emerged to address this challenge:

SHL Medical Reunite: A dual-chamber cartridge autoinjector that automates the reconstitution process. The drug powder and diluent are stored in separate chambers within the same cartridge. When the user activates the device, the two chambers are connected, the contents are mixed automatically, and the reconstituted drug is then injected. This eliminates the manual reconstitution step, reducing user error and improving dose consistency.

Ypsomed LyoTwist: A dual-chamber monodose device launched in February 2026. The LyoTwist uses a simple twisting mechanism to connect the drug and diluent chambers, reconstitute the drug, and prepare the injection. The monodose format (single-use) is designed for ease of manufacturing and disposal, and is positioned for GLP-1 and other peptide therapies that require lyophilized formulations.

These platforms represent a significant step forward in drug-delivery device engineering, and they introduce new regulatory considerations around device-drug compatibility, sterilization validation, and combination product testing.

Connected Injection Systems

The digitization of drug delivery is accelerating. In 2025, Ypsomed's SmartPilot received FDA 510(k) clearance -- the first FDA-cleared connectivity device for autoinjector platforms. The SmartPilot captures injection data including time, date, injection outcome (success or failure), and user errors. This data can be transmitted to a companion app and shared with healthcare providers.

Connected injection systems serve multiple purposes in the GLP-1 ecosystem:

• Adherence monitoring: GLP-1 therapies require consistent weekly injection schedules. Connected devices provide objective adherence data that can support patient management and clinical decision-making.
• Dose titration tracking: During dose escalation, connected devices can confirm that patients are administering the correct dose at each step.
• Error detection: Injection failures, incomplete injections, and device malfunctions can be captured and reported, providing real-world performance data that complements clinical trial results.
• Real-world evidence generation: Aggregated, anonymized injection data can support post-market surveillance commitments and inform label updates.

From a regulatory standpoint, connected injection systems occupy an important niche. While the auto-injector pen itself is regulated as a device constituent of a combination product (under the drug's NDA or BLA), a standalone connectivity accessory like the SmartPilot can pursue its own 510(k) clearance. This creates a modular regulatory pathway where the drug-device combination product and the connectivity accessory are regulated through separate but parallel processes.

Oral Delivery Platforms

The emergence of oral GLP-1 therapies -- Wegovy oral (approved December 2025) and Foundayo (approved April 2026) -- introduces a fundamentally different delivery paradigm. However, oral delivery does not eliminate the need for specialized delivery technology.

Wegovy oral uses an absorption enhancer (SNAC, sodium N-[8-(2-hydroxybenzoyl)amino]caprylate) to facilitate the absorption of semaglutide across the gastric mucosa. Patients must take the tablet on an empty stomach with a specific amount of water, and wait at least 30 minutes before eating or drinking. These administration requirements are effectively "device instructions" embedded in the drug label -- and they represent a delivery constraint that impacts patient adherence and real-world effectiveness.

Foundayo (orforglipron) is a non-peptide small molecule that does not require an absorption enhancer. It can be taken without food or water restrictions, making it the most patient-convenient oral GLP-1 option available in 2026. From a device perspective, oral small-molecule GLP-1 products do not require injection devices, potentially reducing the addressable market for pen injectors in the obesity segment while leaving the diabetes injectable market (Ozempic, Mounjaro) largely intact.

Emerging Platforms: Microneedle Patches

Microneedle patches represent an emerging platform for transdermal peptide delivery that could eventually compete with pen injectors for GLP-1 administration. These devices use an array of micron-scale needles to deliver peptide drugs across the stratum corneum without reaching the nerve-rich deeper tissue layers, potentially offering painless self-administration.

As of mid-2026, microneedle delivery of GLP-1 receptor agonists remains in preclinical and early clinical development. The primary challenges are delivering sufficient peptide payload (GLP-1 doses are in the milligram range, which is large by microneedle standards), maintaining peptide stability within the microneedle matrix, and achieving consistent bioavailability. However, the platform has attracted significant investment, and several companies are advancing toward clinical trials.

Regulatory Pathway for GLP-1 Combination Products

FDA Office of Combination Products and Primary Mode of Action

In the United States, GLP-1 injectable products are regulated as combination products under the jurisdiction of the FDA Office of Combination Products (OCP). The OCP determines which FDA center has primary jurisdiction over a combination product based on its Primary Mode of Action (PMoA).

For GLP-1 injectable products, the drug constituent is always the PMoA. The auto-injector pen or delivery device contributes to the therapy but does not achieve the primary intended therapeutic effect. This means the combination product is regulated under a New Drug Application (NDA) or Biologics License Application (BLA), with the Center for Drug Evaluation and Research (CDER) or the Center for Biologics Evaluation and Research (CBER) serving as the lead center.

The device component -- the auto-injector, pen injector, or other delivery system -- is regulated as a device constituent of the combination product under 21 CFR Part 3. This means that while the overall product is approved under an NDA or BLA, the device component must meet applicable device requirements, including design controls, manufacturing controls, and human factors validation.

Device Constituent Requirements within the NDA/BLA

The device constituent of a GLP-1 combination product is not independently cleared or approved through the 510(k) or PMA pathway. Instead, the device information is included within the drug application and reviewed by the lead center with input from the Center for Devices and Radiological Health (CDRH). The following device-related information is typically required:

• Device description and specifications: Detailed engineering drawings, materials of construction, and performance specifications for the delivery device.
• Design control documentation: Evidence that the device was developed under a design control process meeting the requirements of the device Quality Management System Regulation (QMSR, 21 CFR Part 820, now incorporating ISO 13485 by reference).
• Human factors validation study report: A comprehensive study demonstrating that the intended users (patients, and in some cases caregivers) can use the device safely and effectively under conditions of simulated or actual use.
• Device performance testing: Bench testing confirming that the device meets its performance specifications, including dose accuracy, injection force, needle penetration depth, and environmental robustness.
• Biocompatibility assessment: For patient-contact components (needle, drug contact surfaces, exterior surfaces), an assessment per ISO 10993 or equivalent.
• Sterility assurance: Documentation of the sterilization validation for the needle and fluid path components.
• Device-drug compatibility: Extractables and leachables studies, stability data with the drug product in the device, and functional testing after storage under labeled conditions.

Human Factors Engineering for Injection Devices

Human factors engineering (HFE) is one of the most critical elements of the regulatory submission for a GLP-1 combination product. FDA's guidance on human factors for combination products requires manufacturers to demonstrate that the delivery device can be used safely and effectively by its intended users under real-world conditions.

For GLP-1 auto-injectors and pen injectors, a human factors validation study typically includes:

• Use-related risk analysis: A systematic analysis of all possible use errors, their clinical consequences, and the mitigations implemented in the device design and labeling.
• Formative usability studies: Iterative testing during device development to identify and resolve usability issues before the validation study.
• Summative (validation) usability study: A definitive study with representative users (typically 45 or more participants per user group) performing all critical tasks under simulated-use conditions. The study must demonstrate that use errors are rare and that any observed use errors do not result in unacceptable safety risks.

The specific challenges of human factors testing for GLP-1 devices include testing with obese and diabetic patient populations (who may have limited dexterity, visual impairments, or cognitive load from managing complex medication regimens), evaluating dose titration sequences (ensuring patients can correctly select escalating doses), and assessing the impact of device design on adherence.

Combination Product CGMP Requirements

Manufacturers of GLP-1 combination products must comply with Current Good Manufacturing Practice requirements for both the drug and device constituents. This dual compliance requirement is one of the most challenging aspects of combination product manufacturing.

Drug CGMP (21 CFR Parts 210/211): Covers drug substance and drug product manufacturing, including formulation, filling, labeling, and testing. For injectable GLP-1 products, this includes sterile manufacturing, aseptic processing, and end-product sterility testing.

Device QMSR (21 CFR Part 820, now incorporating ISO 13485:2016): As of the February 2, 2026 compliance date, the QMSR replaced the former Quality System Regulation. Device constituent manufacturing must comply with ISO 13485 requirements, plus FDA-specific additions for complaint files, UDI, and record-keeping. This covers design controls, production and process controls, corrective and preventive action (CAPA), and management review for the device component.

For companies that manufacture both the drug and device components, the quality management system must address both sets of requirements in an integrated manner. This is particularly challenging for GLP-1 combination products where the drug and device are manufactured in the same facility or where the final assembly (filling the drug into the device) is performed under sterile conditions.

Standalone Device Regulatory Pathways

Not all device components of the GLP-1 ecosystem are regulated as part of a combination product. Standalone delivery devices and accessories can pursue independent regulatory pathways:

510(k) pathway: Connected injection accessories like the Ypsomed SmartPilot, which is a standalone device that attaches to or interfaces with an autoinjector but does not contain or contact the drug, can pursue 510(k) clearance. The 510(k) submission must demonstrate substantial equivalence to a predicate device in terms of intended use and technological characteristics.

Accessory classification: FDA may classify a connectivity accessory based on the classification of the parent device. If the parent device (the auto-injector) is regulated as part of a combination product, the accessory's classification must be determined through the OCP or through a premarket submission that references the combination product.

EU MDR Requirements for GLP-1 Delivery Devices

Classification Under EU MDR Rule 14

Under the EU Medical Device Regulation (MDR 2017/745), drug-delivery devices -- including auto-injectors, pen injectors, and related administration systems -- are classified under Rule 14. This rule covers "devices that are invasive in body orifices (other than surgically invasive), connected to an active medical device, or intended to administer or remove medicinal products."

Most GLP-1 auto-injector pens and pen injectors are classified as Class IIa under Rule 14, unless they are intended to administer medicinal products in a manner that is potentially hazardous, in which case they may be classified as Class IIb. Factors that can drive classification to Class IIb include the route of administration, the nature of the drug product, and the potential consequences of device malfunction (such as overdose or underdose).

The practical difference between Class IIa and Class IIb is significant: Class IIb devices require conformity assessment by a Notified Body with greater scrutiny of the technical documentation and clinical evidence.

CE Marking and Notified Body Assessment

GLP-1 delivery devices, as the device constituent of a drug-device combination product, require CE marking under the EU MDR. The CE marking process includes:

• Technical documentation: A comprehensive technical file covering device description, specifications, risk analysis, design verification and validation, biocompatibility, usability, and labeling. The technical file must demonstrate compliance with the General Safety and Performance Requirements (GSPR) set out in Annex I of the MDR.
• Notified Body assessment: An independent Notified Body must review the technical documentation and issue an EU Type Examination Certificate (or equivalent, depending on the conformity assessment procedure) for the device. The assessment includes a review of the quality management system.
• Declaration of Conformity: The manufacturer issues an EU Declaration of Conformity, which must be supported by the technical documentation and the Notified Body certificate.

For combination products, the CE marking of the device component is typically handled separately from the marketing authorization of the drug product, although the drug-device interface must be addressed in both submissions.

Key Harmonized Standards

The following harmonized standards are most relevant to GLP-1 delivery devices:

ISO 11608 is the most directly applicable standard family for GLP-1 pen injectors and auto-injectors. Compliance with the relevant parts of ISO 11608 is effectively expected by both FDA and EU Notified Bodies for these devices.

GLP-1 Compounding and FDA Enforcement: Impact on Device Manufacturers

FDA's Escalating Enforcement Actions

The compounding of GLP-1 receptor agonists has been a persistent challenge since the rapid uptake of semaglutide and tirzepatide outpaced manufacturing capacity. Compounding pharmacies and telehealth companies began offering non-approved versions of these drugs, sometimes with non-sterile or non-pharmaceutical-grade active pharmaceutical ingredients (APIs), delivered in unapproved injection devices.

FDA has taken a series of escalating enforcement actions:

• December 2024: FDA declared the tirzepatide shortage resolved, removing the compounding exemption under Section 503A.
• February 2025: FDA declared the semaglutide shortage resolved, similarly removing the compounding exemption.
• February 6, 2026: FDA announced decisive enforcement against non-approved compounded GLP-1 drugs, signaling an escalation in warning letters, import alerts, and enforcement actions.
• March 2026: FDA issued warning letters to telehealth companies, including Mile High Compounds, for distributing non-approved compounded GLP-1 products.
• April 1, 2026: FDA clarified compounding policies, specifying that 503A pharmacies are limited to four prescriptions per month of "essentially a copy" products, and that 503B outsourcing facilities must meet heightened requirements for GLP-1 compounding.
• Import alert: FDA established an import alert targeting GLP-1 APIs from non-vetted manufacturers, blocking entry of suspect raw materials.

Implications for Device Manufacturers

The compounding market has created a parallel ecosystem of unapproved injection devices -- prefilled syringes, pen-like devices, and vial-and-syringe configurations -- that do not meet the regulatory standards applicable to legitimate combination product delivery devices. For device manufacturers, this creates several concerns:

• Market confusion: Patients and some healthcare providers may not distinguish between FDA-approved combination products (with validated delivery devices) and compounded alternatives (with untested delivery systems). Adverse events associated with compounded products may be misattributed to the approved product.
• Regulatory scrutiny: FDA's enforcement actions against compounding may extend to manufacturers of components or devices that are used in compounded GLP-1 products. Device companies should ensure that their distribution channels do not facilitate compounding operations.
• Legitimate market protection: The enforcement actions protect the market position of approved combination products and their validated delivery devices. Device manufacturers partnering with approved drug sponsors benefit from this enforcement.

Supply Chain and Manufacturing Considerations

Device Component Supply Chain Strain

The explosive growth in GLP-1 demand has placed extraordinary strain on the injection device supply chain. Key components under stress include:

• Glass cartridges: Pre-filled pen injectors use borosilicate glass cartridges to store the drug product. The global glass cartridge manufacturing capacity has been insufficient to meet GLP-1 demand, creating long lead times and allocation challenges.
• Pen mechanisms: The mechanical components of pen injectors -- springs, plungers, dose selectors, and needle shields -- require precision manufacturing and assembly. Scaling production from tens of millions to hundreds of millions of units annually has been a multi-year effort.
• Sterile needles: GLP-1 pen injectors require integrated sterile needles. Needle manufacturing, sterilization, and integration into pen assemblies represent a critical bottleneck.
• Electronic components: Connected injection systems require sensors, microcontrollers, wireless communication modules, and batteries. These components compete with demand from consumer electronics and automotive industries.

Manufacturing Expansion

In response to these supply chain pressures, major suppliers are investing in expanded capacity. In March 2026, West Pharmaceutical Services opened a 165,000 square foot expansion at its Dublin, Ireland facility dedicated to high-volume injectable therapy manufacturing, including next-generation GLP-1 treatments. Other suppliers, including SCHOTT Pharma and Gerresheimer, have similarly announced capacity expansion projects.

Dual-Chamber Cartridge Manufacturing Challenges

The introduction of dual-chamber reconstitution devices adds new manufacturing complexity. Dual-chamber cartridges must maintain:

• Sterile separation: The drug chamber and diluent chamber must be independently sterile and must remain separated until the point of activation.
• Consistent geometry: The cartridge geometry must be precise enough to ensure reliable mixing and complete drug delivery across millions of units.
• Compatibility: The materials of construction must be compatible with both the lyophilized drug and the diluent, without extractables or leachables that could affect drug stability or safety.
• Integrated testing: Each dual-chamber cartridge must be tested for seal integrity, drug content, diluent content, and functionality before release.

Device-Drug Integration Testing

For any GLP-1 combination product, the interaction between the drug and the device must be thoroughly characterized through:

• Extractables and leachables studies: Identifying and quantifying any chemical substances that migrate from device materials into the drug product, both during storage and during the injection process.
• Stability studies: Demonstrating that the drug product remains stable (chemically, physically, and microbiologically) when stored in the device throughout the labeled shelf life and under the labeled storage conditions.
• Functional testing after storage: Confirming that the device performs according to its specifications (dose accuracy, injection force, needle deployment) after storage with the drug product under real-world conditions.
• Shipping and distribution testing: Simulating the mechanical and thermal stresses of distribution to confirm that the combination product arrives at the patient in a functional and safe condition.

Comparison of GLP-1 Delivery Platform Regulatory Requirements

The following table summarizes the regulatory pathway, device classification, and key standards for each major delivery platform type in the GLP-1 ecosystem:

Future Outlook: 2027-2028

Injectable vs. Oral Delivery: Coexistence, Not Replacement

The emergence of oral GLP-1 therapies will not eliminate the need for injectable delivery devices. Several factors support continued demand for injection devices:

• Efficacy gap: Current data suggests that injectable GLP-1 receptor agonists achieve higher rates of weight loss and glycemic control than oral formulations. For patients with severe obesity or inadequately controlled diabetes, injectables remain the preferred therapeutic option.
• Dose flexibility: Injectable formulations allow for precise dose titration that may be more limited with fixed-dose oral tablets.
• New injectable products: The pipeline includes next-generation injectable products (retatrutide, CagriSema, VK2735 injectable) that are expected to enter the market in 2027-2028, each requiring its own delivery device.
• Patient preference: While oral delivery is more convenient, some patients and physicians prefer the once-weekly injection schedule of GLP-1 pen injectors over daily oral dosing.

Connected and Smart Injection Devices as Standard

The clearance of Ypsomed's SmartPilot in 2025 established a regulatory precedent for connected injection accessories. By 2027-2028, connectivity features are expected to become standard in new GLP-1 delivery devices, either integrated into the pen injector or as add-on accessories. This trend will require device manufacturers to invest in:

• Software development and cybersecurity: Connected devices require robust software, secure data transmission, and compliance with FDA cybersecurity requirements (including Software Bills of Materials).
• Data privacy and compliance: Injection data is health information subject to HIPAA (in the US) and GDPR (in the EU). Device manufacturers must implement appropriate data protection measures.
• Real-world evidence infrastructure: The ability to collect, analyze, and report real-world injection data will become a competitive differentiator and may support post-market commitments.

Next-Generation Delivery Platforms

Several next-generation delivery platforms are expected to advance toward commercialization in the 2027-2028 timeframe:

• Microneedle patches: If clinical trials are successful, microneedle delivery of GLP-1 peptides could offer a less invasive alternative to needle-based injection.
• Implantable pumps: Long-acting GLP-1 formulations delivered via implantable pumps could enable once-monthly or less frequent dosing, reducing the device burden on patients.
• Longer-acting formulations: Extended-release formulations requiring less frequent injection (monthly or quarterly) would change the device demand profile, potentially reducing the total number of devices needed per patient per year.

EU Regulatory Simplification

The European Commission's proposal to simplify certain aspects of the EU MDR and IVDR, if adopted, could affect the regulatory requirements for GLP-1 delivery device components by the second quarter of 2027. Potential changes include streamlined conformity assessment procedures, extended transition timelines, and reduced administrative burden for certain device classes. Device manufacturers should monitor these developments closely, as they could impact the timeline and cost of CE marking for new delivery devices.

Key Takeaways for Device Manufacturers

Strategic Recommendations

Regulatory Pathway Decision Framework

The following decision framework can help device manufacturers determine the appropriate regulatory pathway for GLP-1 delivery components:

1. Does the device contain or directly contact the drug product?

   • Yes: The device is a constituent of a combination product. It will be regulated under the drug's NDA or BLA. Engage the drug sponsor and OCP early.
   • No: The device may be eligible for standalone regulatory pathways (510(k), De Novo, or CE marking under MDR). Determine classification and identify predicates.

2. Does the device have electronic or connectivity features?

   • Yes: Additional requirements apply, including IEC 60601-1 compliance, cybersecurity documentation, and potentially a separate 510(k) for the connectivity module.
   • No: Standard mechanical device requirements apply (ISO 11608 series, ISO 10993-1, IEC 62366-1).

3. Is the device intended for reconstitution of a lyophilized product?

   • Yes: Additional requirements for dual-chamber systems apply (ISO 11608-5), including mixing validation, sterility assurance for both chambers, and drug-device compatibility studies specific to the lyophilized and reconstituted states.

4. Will the device be marketed in the EU?

   • Yes: Determine classification under MDR Rule 14 (typically Class IIa or IIb), engage a Notified Body, and prepare technical documentation per MDR Annex II and III.

Conclusion

The GLP-1 drug-delivery device ecosystem in 2026 is characterized by extraordinary growth, rapid innovation, and complex regulatory requirements. The approval of oral GLP-1 therapies has expanded the treatment landscape but has not diminished the critical importance of injection devices, which remain the delivery platform for the highest-efficacy GLP-1 products and the next generation of combination therapies entering the pipeline.

For device manufacturers, the opportunity is substantial but the regulatory bar is high. Combination product pathways require expertise in both drug and device regulation, human factors engineering must address diverse and complex patient populations, and the transition to connected devices adds cybersecurity and data privacy requirements to an already demanding compliance landscape. The manufacturers that succeed will be those that invest early in regulatory strategy, build integrated quality systems, secure their supply chains, and maintain close engagement with both FDA and EU Notified Bodies throughout the product lifecycle.

The GLP-1 market shows no signs of slowing. With over 30 compounds in active development for obesity, multiple next-generation combination therapies approaching regulatory submission, and an expanding patient population driven by improved access programs, the demand for safe, effective, and user-friendly drug-delivery devices will continue to grow through 2027 and beyond.